fatty liver disease and semaglutide Focus on 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis Novo Nordisk will file semaglutide

Wash your hands Wash your hands with soap and warm water to prevent potential infection

Clinical research involving thousands of participants has established that semaglutide demonstrates an overall favorable risk/benefit profile with semaglutide producing mostly mild-to-moderate and transient side effects, primarily gastrointestinal in nature

Originally developed for managing type 2 diabetes, semaglutide has also been approved at a higher dose (2.4 mg) for the treatment of obesity

Increased heart rate: A resting heart rate that suddenly feels fast or pounding should be reported to your provider

Clinical trials show semaglutide reduces systolic blood pressure by around 3.5-5 mmHg compared to placebo, likely due to weight loss and direct metabolic effects